Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment

Psychosomatic Medicine

Volumn 67, Issue 6, 2005, Pages 1013-1021

  Ironson, Gail ^a   O'Cleirigh, Conall ^a   Fletcher, Mary Ann ^b   Laurenceau, Jean Philippe ^a   Balbin, Elizabeth ^a   Klimas, Nancy ^b   Schneiderman, Neil ^a,b   Solomon, George ^c  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Adherence; Coping; Depression; Disease progression; HIV AIDS; Stress

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; AVOIDANCE BEHAVIOR; COPING BEHAVIOR; DEMOGRAPHY; DEPRESSION; DISEASE COURSE; EDUCATION; ETHNIC GROUP; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOPELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EVENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL ENVIRONMENT; SOCIAL SUPPORT; STRESS; SYMPTOMATOLOGY; VIRUS LOAD; ADAPTIVE BEHAVIOR; BLOOD; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; MENTAL STRESS; PERSONALITY TEST; PROGNOSIS; PSYCHOLOGICAL ASPECT; SEX DIFFERENCE; SOCIAL CLASS; STATISTICAL MODEL; UTILIZATION REVIEW; VIROLOGY;

ADAPTATION, PSYCHOLOGICAL; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEPRESSIVE DISORDER; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; LIFE CHANGE EVENTS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; PATIENT COMPLIANCE; PERSONALITY INVENTORY; PROGNOSIS; SEX FACTORS; SOCIAL CLASS; SOCIAL SUPPORT; STRESS, PSYCHOLOGICAL; VIRAL LOAD;

EID: 33645633212     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.psy.0000188569.58998.c8     Document Type: Article

References (59)

1. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA 1993;270:2568-73.
2. Page-Shafer K, Delorenze GN, Satariano WA, Winkelstein W Jr. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol 1996;6:420-30.
3. Leserman J, Jackson ED, Petitto JM, Golden RN, Silva SG, Perkins DO, Cai J, Folds JD, Evans DL. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med 1999;61:397-406.
4. Leserman J, Petitto JM, Gu H, Gaynes BN, Barroso J, Golden RN, Perkins DO, Folds JD, Evans DL. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med 2002;32:1059-73.
5. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003;54:295-306.
6. Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC, Coates TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med 1996;156:2233-8.
7. Patterson TL, Shaw WS, Semple SJ, Cherner M, McCutchan A, Atkinson H, Grant I, Nannis E. Relationship of psychosocial factors to HIV disease progression. Ann Behav Med 1996;18:30-9.
8. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, Moore J. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001;285:1460-5.
9. Patterson TL, Semple SJ, Temoshok LR, Atkinson JH, McCutchan JA, Straits-Troster K, Chandler JL, Grant I. Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men: HIV Neurobehavioral Research Center Group. Psychiatry 1995;58:299-312.
10. Kemeny ME, Dean L. Effects of AIDS-related bereavement on HIV progression among New York City gay men. AIDS Educ Prev 1995;7(suppl):36-47.
11. Ironson G, Friedman A, Klimas N, Antoni M, Fletcher M, LaPerriere A, Simoneau J, Schneiderman N. Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with human immunodeficiency virus. Int J Behav Med 1994;1:90-105.
12. Coates TJ, Stall R, Ekstrand M, Solomon G. Psychological predictors as cofactors for disease progression in men infected with HIV: the San Francisco men's health study. Presented at the V International AIDS Conference, Montreal, Canada; 1989.
13. Leserman J, Petitto JM, Golden RN, Gaynes BN, Gu H, Perkins DO, Silva SG, Folds JD, Evans DL. Impact of stressful life events, depression, social support, coping and cortisol on progression to AIDS. Am J Psychiatry 2000;157:1221-8.
14. Solano L, Costa M, Salvati S, Coda R, Aiuti F, Mezzaroma I, Bertini M. Psychosocial factors and clinical evolution in HIV-1 infection: a longitudinal study. J Psychosom Res 1993;37:39-51.
15. Mulder CL, Antoni MH, Dulvenvoorden HJ, Kauffmann RH, Goodkin K. Active confrontational coping predicts decreased clinical progression over a one-year period in HIV-infected homosexual men. J Psychosom Res 1995;39:957-65.
16. Vassend O, Eskild A, Halvorsen R. Negative affectivity, coping, immune status, and disease progression in HIV infected individuals. Psychol Health 1997;12:375-88.
17. Blomkvist V, Theorell T, Jonsson H, Schulman S, Berntorp E, Stiegendal L. Psychosocial self prognosis in relation to mortality and morbidity in hemophiliacs with HIV infection. Psychother Psychosom 1994;62:185-92.
18. Theorell T, Blomvist V, Jonsson H, Schulman S, Berntorp E, Stigendal L. Social support and the development of immune function in human immunodeficiency virus infection. Psychosom Med 1995;57:32-5.
19. Perry S, Fishman B, Jacobsberg L, Frances A. Relationships over 1 year between lymphocyte subsets and psychosocial variables among adults with infection by human immunodeficiency virus. Arch Gen Psychiatry 1992;49:396-401.
20. Miller G, Kemeny M, Taylor S, Cole S, Visscher B. Social relationships and immune processes in HIV seropositive gay and bisexual men. Ann Behav Med 1997;19:139-51.
21. Sage MS, Holodnly M, Kuirzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
22. Powderly WG, Landry A, Lederman M. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998;280:72-7.
23. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA. Antiretroviral therapy in adults: updated recommendations from the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
24. Kalichman SC, Ramachandran B, Ostrow D. Protease inhibitors and the new AIDS combination therapies: implications for psychological services. Prof Psychol Res Pract 1998;29:349-56.
25. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 1997;50:385-91.
26. Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, Harrington RD, Holmes KK. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 2004;15:803-10.
27. Castillo E, Palepu A, Beardsell A, Akagi L, Yip B, Montaner JS, Hogg RS. Outpatient pharmacy care and HIV viral load response among patients on HAART. AIDS Care 2004;16:446-57.
28. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy MG, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
29. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19:124-33.
30. Stansell J, Holtzer C, Mayer S, DeGuzman D, Hamel E, Lapins D. Factors affecting treatment outcomes in a medication event monitoring system. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL; 2001.
31. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-83.
32. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Patient Care Committee and Adherence Working Group of the Adult AIDS Clinical Trials Group: self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the ACTG adherence instruments. AIDS Care 2000;12:255-66.
33. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol 1997;54:S91-8.
34. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 1998;10:297-312.
35. rd Annual Conference of the Society for Behavioral Medicine, Boston, MA; 2005.
36. Riera M, La Fuente LdL, Castanyer B. Adherence to antiretroviral therapy measured by pill count and drug serum concentrations: variables associated with a bad adherence. Med Clin 2002;119:286-262.
37. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psych 1961;4:561-71.
38. Kendall PC, Hollon SD, Beck AT, Hammen CL, Ingram RE. Issues and recommendations regarding use of the Beck Depression Inventory. Cogn Ther Res 1987;11:289-99.
39. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the Hopelessness Scale. J Consult Clin Psychol 1974;42:861-5.
40. Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol 1989;56:267-83.
41. Sarason IG, Johnson J, Siegel J. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychology 1978;46:932-46.
42. Mitchell PH, Powell L, Blumenthal J, Norten J, Ironson G, Pitula CR, Froelicher ES, Czajkowski S, Youngblood M, Huber M, Berkman LF. A short social support measure for patients recovering from myocardial infarction: the ENRICHD Social Support Inventory. J Cardiopulm Rehabil 2003;23:398-403.
43. Raudenbush SW, Bryk AS, Cheong YF, Congdon RC. HLM5: Hierarchical Linear and Nonlinear Modeling. Lincolnwood, IL: Scientific Software International; 2002.
44. Bryk AS, Raudenbush SW. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd ed. Thousand Oaks, CA: Sage; 2002.
45. Balbin EG, Ironson GH, Solomon GF. Stress and coping: the psychoneuroimmunology of HIV/AIDS. Best Pract Res Clin Endocrinol Metab 1999;13:615-33.
46. Kiecolt-Glaser JK, Glaser R. Methodological issues in behavioral immunology research with humans. Brain Behav Immunol 1988;2:67-78.
47. Lyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA, Wesch J, VanRaden MJ, Treisman GJ, Morgenstern H. Depressive symptoms as predictors of medical outcomes in HIV infection. JAMA 1993;270:2563-7.
48. Adler NE, Boyce T, Chesney MA, Cohen S, Folkman S, Kahn RL, Syme SL. Socioeconomic status and health; the challenge of the gradient. Am Psychol 1994;49:15-24.
49. Kopnisky KL, Stoff DM, Rausch DM. Workshop report: the effects of psychological variables on the progression of HIV-1 disease. Brain Behav Immunol 2004;8:246-61.
50. Corley PA. Acquired immune deficiency syndrome: the glucocorticoid solution. Med Hypotheses 1996;47:49-54.
51. Cole SW, Korin YD, Fahey JL, Zack JA. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol 1998;161:610-6.
52. Cole SW, Naliboff BD, Kemeny ME, Griswold MP, Fahey JL, Zack JA. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci U S A 2001;98:12695-700.
53. Evans DL, Leserman J, Perkins DO, Stern RA, Murphy C, Zheng B, Gettes D, Longmate JA, Silva SG, van der Horst CM, Hall CD, Folds JD, Golden RN, Petitto JM. Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry 1997;154:630-4.
54. Ironson G, Balbin E, Solomon G, Schneiderman N, Fahey J, Fletcher MA. Relative preservation of natural killer cell cytotoxicity and number in healthy AIDS patients with low CD4 counts. AIDS 2001;15:2065-72.
55. Zisook S, Perterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. J Clin Psychiatry 1998;59:217-24.
56. Rabkin J, Wagner G, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry 1999;156:101-7.
57. Markowitz J, Kocsis J, Fishman B, Spielman L, Jocobsberg L, Frances A, Klerman G, Perry S. Treatment of depressive symptoms in HIV-positive patients. Arch Gen Psychiatry 1998;55:452-57.
58. Safren S, Hendriksen E, Mayer K, Mimiaga M, Pickard R, Otto M. Cognitive behavioral therapy for HIV medication adherence and depression. Cogn Behav Pract 2004;11:415-23.
59. Antoni M, Carrioo AW, Duran RE, Spitzer S, Penedo F, Ironson G, Fletcher MA, Klimas N, Schneiderman N. Randomized clinical trial of cognitive behavioral stress management on HIV viral load in gay men treated with HAART. Psychosom Med; in press.